Drug Shortage Report for ETOMIDATE INJECTION, USP
| Report ID | 273806 |
| Drug Identification Number | 02537508 |
| Brand name | ETOMIDATE INJECTION, USP |
| Common or Proper name | Etomidate Injection, USP 2mg/mL, 10 mL, vial |
| Company Name | FRESENIUS KABI CANADA LTD |
| Market Status | MARKETED |
| Active Ingredient(s) | ETOMIDATE |
| Strength(s) | 2MG |
| Dosage form(s) | SOLUTION |
| Route of administration | INTRAVENOUS |
| Packaging size | 10 mL |
| ATC code | N01AX |
| ATC description | |
| Reason for shortage | Disruption of the manufacture of the drug. |
| Anticipated start date | 2025-12-22 |
| Actual start date | |
| Estimated end date | 2026-01-22 |
| Actual end date | |
| Shortage status | Anticipated shortage |
| Updated date | 2025-12-08 |
| Company comments | Fresenius Kabi Canada regrets to advise that due to production delays, we have encountered a supply interruption on our Etomidate Injection, USP 2 mg/mL, 10 mL, vial, effective December 22, 2025, until January 22, 2026 |
| Health Canada comments | |
| Tier 3 Status | No |
| Contact Address | 165 GALAXY BLVD, SUITE 100 TORONTO, ONTARIO CANADA M9W 0C8 |
| Company contact information |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
| Version Number | Date Updated | Language | |
|---|---|---|---|
| v3 | 2025-12-08 | French | Compare |
| v2 | 2025-12-08 | English | Compare |
| v1 | 2025-12-08 | English | Compare |
Showing 1 to 3 of 3